Study of surgery options and quality of life in pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study looks at people with borderline-resectable or locally advanced pancreatic cancer to see how treatment choices affect survival, quality of life, and whether tumors can be removed by surgery. It may help doctors better predict who can benefit from surgical approaches and what outcomes matter most to patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a pancreatic tumor that is confirmed or suspected (primary pancreatic cancer).
- Your cancer has been described as borderline resectable or locally advanced using cancer guideline criteria.
- Your doctors do not think it is an endocrine (hormone-producing) tumor.
- Your tumor is not thought to be a non-pancreatic periampullary (near the pancreas) tumor.
- Your cancer has not spread to distant parts of the body (no distant metastasis).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new way to treat pancreatic cancer that has spread to nearby tissues but not to distant organs. It uses a tailored plan that may include chemotherapy and possibly surgery. The goal is to see if this personalized approach helps people live longer and better.
This study looks at pancreatic cancer patients who undergo planned surgery and how surgery-related factors relate to outcomes. It especially focuses on pre-surgery CT scans and the “margin” status from the pathology report, which may help doctors better plan treatment.
This trial is testing whether surgery can help people with a certain type of pancreatic cancer that is locally advanced but not yet spread. You may join if your cancer has shrunk or stayed stable after at least 4 months of chemotherapy and your medical team thinks surgery is possible.
This trial studies whether giving chemotherapy before surgery, and possibly adding a focused high-dose radiation treatment, can improve outcomes for people with borderline resectable pancreatic cancer. It aims to shrink or control the cancer and help more patients get to surgery safely.
This study looks at using a special blood test (ctDNA MRD) to track how well the tumor responds to chemotherapy before surgery for pancreatic cancer. It may help doctors decide if the treatment is working and guide next steps.
This trial studies an “implementation program” to help patients with locally advanced pancreatic cancer get ready for the next steps after chemotherapy. It may help improve care planning and outcomes for people whose cancer has not grown after initial treatment.
Hear when a new Pancreas Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.